127 related articles for article (PubMed ID: 2354227)
41. 3H-spiroperidol binding to peripheral mononuclear cells in schizophrenic and healthy subjects.
Wodarz N; Fritze J; Riederer P; Beckmann H
Biol Psychiatry; 1993 May; 33(10):727-33. PubMed ID: 8353168
[TBL] [Abstract][Full Text] [Related]
42. Prolactin bioassay in schizophrenia before and after neuroleptics.
Peabody CA; Warner MD; Griffin M; Boutros NN; Worsley IG; Friesen HG
Psychiatry Res; 1992 Mar; 41(3):249-55. PubMed ID: 1594711
[TBL] [Abstract][Full Text] [Related]
43. Effective resolution with olanzapine of acute presentation of behavioral agitation and positive psychotic symptoms in schizophrenia.
Kinon BJ; Roychowdhury SM; Milton DR; Hill AL
J Clin Psychiatry; 2001; 62 Suppl 2():17-21. PubMed ID: 11232746
[TBL] [Abstract][Full Text] [Related]
44. Changes in central serotonergic function as a correlate of duration of illness in paranoid schizophrenia.
Angelopoulos EK; Markianos M; Daskalopoulou EG; Hatzimanolis J; Tzemos J
Psychiatry Res; 2002 May; 110(1):9-17. PubMed ID: 12007589
[TBL] [Abstract][Full Text] [Related]
45. Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
Tollefson GD; Beasley CM; Tran PV; Street JS; Krueger JA; Tamura RN; Graffeo KA; Thieme ME
Am J Psychiatry; 1997 Apr; 154(4):457-65. PubMed ID: 9090331
[TBL] [Abstract][Full Text] [Related]
46. [Prolactinemia and predictability of therapeutic response of schizophrenic patients in acute decompensation].
Vanelle JM; Amorim P; Piketti ML; Bourdel MC; Poirier-Littré MF
Encephale; 1996 Oct; 22 Spec No 3():82-4. PubMed ID: 8954284
[No Abstract] [Full Text] [Related]
47. Haloperidol blood levels and effects in schizophrenia and schizoaffective disorder: a progress report.
Volavka J; Cooper TB; Meisner M; Bitter I; Czobor P; Jaeger J
Psychopharmacol Bull; 1990; 26(1):13-7. PubMed ID: 2371368
[TBL] [Abstract][Full Text] [Related]
48. Effects of treatment with various doses of haloperidol on the pituitary-gonadal axis in male schizophrenic patients.
Rinieris P; Hatzimanolis J; Markianos M; Stefanis C
Neuropsychobiology; 1989; 22(3):146-9. PubMed ID: 2485861
[TBL] [Abstract][Full Text] [Related]
49. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group.
Arvanitis LA; Miller BG
Biol Psychiatry; 1997 Aug; 42(4):233-46. PubMed ID: 9270900
[TBL] [Abstract][Full Text] [Related]
50. Schneider's first-rank symptoms of schizophrenia. An association with increased growth hormone response to apomorphine.
Whalley LJ; Christie JE; Brown S; Arbuthnott GW
Arch Gen Psychiatry; 1984 Nov; 41(11):1040-3. PubMed ID: 6497565
[TBL] [Abstract][Full Text] [Related]
51. Serum prolactin response to chlorpromazine and psychopathology in schizophrenics: implications for the dopamine hypothesis.
Meltzer HY; Busch D
Psychiatry Res; 1983 Aug; 9(4):285-99. PubMed ID: 6580661
[TBL] [Abstract][Full Text] [Related]
52. Neuroleptic treatment, symptoms of schizophrenia, and plasma homovanillic acid concentrations revisited.
Volavka J; Douyon R; Convit A; Czobor P; Cooper TB
Arch Gen Psychiatry; 1992 Dec; 49(12):999-1000. PubMed ID: 1449388
[No Abstract] [Full Text] [Related]
53. An abnormal relation between basal prolactin levels and prolactin response to 12.5 microg TRH i.v. in drug-naïve patients with first-episode schizophrenia.
Spoov J; Bredbacka PE; Stenman UH
Schizophr Res; 2010 Jun; 119(1-3):41-6. PubMed ID: 20347273
[TBL] [Abstract][Full Text] [Related]
54. Noradrenergic and dopaminergic interrelation in schizophrenia.
Brambilla F; Marini S; Saito A; Fassone G; Picardi A; Nerozzi D; Pancheri P
Psychiatry Res; 1994 Sep; 53(3):231-42. PubMed ID: 7870845
[TBL] [Abstract][Full Text] [Related]
55. Stability of serum neuroleptic and prolactin concentrations during short- and long-term treatment of schizophrenic patients.
Rao ML; Brown WA
Psychopharmacology (Berl); 1987; 93(2):237-42. PubMed ID: 2892222
[TBL] [Abstract][Full Text] [Related]
56. Acute weight gain, gender, and therapeutic response to antipsychotics in the treatment of patients with schizophrenia.
Ascher-Svanum H; Stensland M; Zhao Z; Kinon BJ
BMC Psychiatry; 2005 Jan; 5():3. PubMed ID: 15649317
[TBL] [Abstract][Full Text] [Related]
57. Evaluating prolactin response to dopamine agonists in schizophrenia. Methodological problems.
Davis BM; Davis KL; Mohs RC; Mathé AA; Rothpearl AB; Johns CA; Levy MI; Horvath TB
Arch Gen Psychiatry; 1985 Mar; 42(3):259-64. PubMed ID: 3977547
[TBL] [Abstract][Full Text] [Related]
58. Plasma prolactin concentration and psychopathology of schizophrenia.
Otani K; Kondo T; Ishida M; Tanaka O; Yasui N; Suzuki A; Kaneko S
Prog Neuropsychopharmacol Biol Psychiatry; 1996 Nov; 20(8):1369-74. PubMed ID: 9004343
[TBL] [Abstract][Full Text] [Related]
59. Enhancement of the prolactin response to d-fenfluramine in drug-naive schizophrenic patients.
Abel KM; O'Keane V; Murray RM
Br J Psychiatry; 1996 Jan; 168(1):57-60. PubMed ID: 8770429
[TBL] [Abstract][Full Text] [Related]
60. Effects of cabergoline on hyperprolactinemia, psychopathology, and sexual functioning in schizophrenic patients.
Kalkavoura CS; Michopoulos I; Arvanitakis P; Theodoropoulou P; Dimopoulou K; Tzebelikos E; Lykouras L
Exp Clin Psychopharmacol; 2013 Aug; 21(4):332-41. PubMed ID: 23834553
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
